SentreHEART Acquisition

8/13/2019

M&A

$300,000,000

Under the terms of the agreement to acquire SentreHEART, the transaction consideration consists of an upfront payment of approximately $40 million in cash and AtriCure common stock, plus additional contingent consideration based on the achievement of certain clinical and reimbursement milestones over the next several years, all of which are value-creating events. Of the contingent consideration, $140 million is based on milestones related to the aMAZE� IDE clinical trial, including PMA approval, and $120 million is based on a milestone related to reimbursement for the therapy involving SentreHEART devices. All contingent consideration would be payable in a combination of cash and stock.

Acquired or Merged

Medical Devices & Instruments

300 Saginaw Dr.
Redwood City, CA 94063
USA

SentreHEART, Inc. is developing minimally invasive devices to protect and treat disorders of the heart.